IGM | Jotup

IGM Biosciences to Present at the Jefferies Healthcare Conference

Retrieved on:

Mittwoch, Mai 29, 2024

IGM, Immunoglobulin M, Webcast, Conference

MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.

Key Points:

MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

Mittwoch, Mai 8, 2024

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.

Key Points:

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.
Collaboration Revenue: For the first quarter of 2024 and 2023, collaboration revenues were $0.5 million in each quarter.
Research and Development (R&D) Expenses: For the first quarter of 2024, R&D expenses were $43.8 million, compared to $50.9 million for the first quarter of 2023.
General and Administrative (G&A) Expenses: For the first quarter of 2024, G&A expenses were $10.5 million, compared to $13.0 million for the first quarter of 2023.

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

Retrieved on:

Dienstag, Mai 7, 2024

Immunoglobulin M, IGM, EDT, Conference, Webcast

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT.

Key Points:

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

IGM Financial Inc. Announces Election of Directors

Retrieved on:

Freitag, Mai 3, 2024

MB, IGM, TSX, Proxy, Annual general meeting

WINNIPEG, MB, May 3, 2024 /CNW/ - IGM Financial Inc. (TSX: IGM) held its Annual Meeting of Shareholders earlier today.

Key Points:

WINNIPEG, MB, May 3, 2024 /CNW/ - IGM Financial Inc. (TSX: IGM) held its Annual Meeting of Shareholders earlier today.
All of the nominees for election as directors listed in its management proxy circular dated February 23, 2024 were elected by a majority of the votes cast by ballot or represented by proxy at the meeting.
The results of the vote by ballot are set out below.

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Retrieved on:

Mittwoch, April 17, 2024

Immunoglobulin M, IGM, Antibody, Sanofi

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.

Key Points:

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.
IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration.
“We are very pleased with our collaboration with Sanofi and with the preclinical data that we have generated in both the immunology/inflammation and the oncology portions of the collaboration,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
IGM will be eligible to receive up to $1,065 million in aggregate development, regulatory and commercial milestones per target as well as tiered high single-digit to low-teen royalties on global net sales.

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Retrieved on:

Mittwoch, April 10, 2024

Immunoglobulin M, IGM, EDT, Webcast

MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT.

Key Points:

MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations .
A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

IGM Financial Recognized as Top Employer by Mediacorp Across Multiple Categories

Retrieved on:

Dienstag, April 16, 2024

TSX, Mackenzie Investments, Workplace, History, MB, Power Corporation of Canada, BRG, Interface (computing), IGM, Mediacorp, Woman

Company identified as one of Canada's Greenest and Best Diversity Employers, as well as one of Manitoba's Top Employers

Key Points:

Company identified as one of Canada's Greenest and Best Diversity Employers, as well as one of Manitoba's Top Employers
WINNIPEG, MB, April 16, 2024 /CNW/ - IGM Financial Inc. (IGM) (TSX: IGM) today announced it has been recognized as a top employer for 2024 in multiple categories by Media Corp Canada Inc. (Mediacorp), including Canada's Greenest Employers, Canada's Best Diversity Employers and Manitoba's Top Employers.
These latest recognitions follow IGM having been recognized by Mediacorp as one of Canada's Top 100 Employers for 2024 last November.
Mediacorp compiles rankings in a number of special-interest and regional competitions, recognizing companies that provide their employees with an exceptional workplace.
"It's extremely encouraging to see that our ongoing commitment to make IGM an outstanding workplace is being recognized with these awards," said Cynthia Currie, Executive Vice-President and Chief Human Resources Officer, IGM Financial.

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Retrieved on:

Dienstag, April 2, 2024

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.

Key Points:

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.
Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
“Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies,” said Steve Davis, Chief Executive Officer.
She joined Horizon in 2018 and served in roles of increasing responsibility that culminated at Executive Vice President, Research and Development.

IGM Financial Inc. to announce first quarter 2024 results on May 2, 2024

Retrieved on:

Donnerstag, März 21, 2024

MB, Power Corporation of Canada, Webcast, PIN, Mackenzie Investments, Magazine, Calendar, TSX, IGM

WINNIPEG, MB, March 21, 2024 /CNW/ - IGM Financial Inc. (TSX: IGM) will announce its first quarter 2024 results after markets close on Thursday, May 2, 2024.

Key Points:

WINNIPEG, MB, March 21, 2024 /CNW/ - IGM Financial Inc. (TSX: IGM) will announce its first quarter 2024 results after markets close on Thursday, May 2, 2024.
A live webcast of IGM Financial's first quarter 2024 results conference call will be available at Quarterly reporting (igmfinancial.com) on Friday, May 3 at 7am CT/8am ET.
James O'Sullivan, President and Chief Executive Officer, IGM Financial Inc., Luke Gould, President and Chief Executive Officer, Mackenzie Investments, Damon Murchison, President and Chief Executive Officer, IG Wealth Management and Keith Potter, Executive Vice-President and Chief Financial Officer, IGM Financial Inc., will participate in the call.
An archived version of the webcast will also be available on IGM Financial Inc.'s website.

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on:

Donnerstag, März 7, 2024

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.

Key Points:

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.
Collaboration Revenue: For the fourth quarter and year ended 2023, collaboration revenues were $0.7 million and $2.1 million, respectively, compared to $0.4 million and $1.1 million for the fourth quarter and year ended 2022, respectively.
Research and Development (R&D) Expenses: For the fourth quarter and year ended 2023, R&D expenses were $54.2 million and $215.5 million, respectively, compared to $45.0 million and $179.3 million for the fourth quarter and year ended 2022, respectively.
General and Administrative (G&A) Expenses: For the fourth quarter and year ended 2023, G&A expenses were $11.6 million and $50.1 million, respectively, compared to $11.6 million and $49.7 million for the fourth quarter and year ended 2022, respectively.